Neurocrine Biosciences Inc vs Tyson Foods, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Tyson Foods, Inc. trades at $57.25 (market cap $20.42B). The key difference: Tyson Foods, Inc. is the larger of the two by market cap, and Tyson Foods, Inc. pays a 3.52% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | TSN | |
|---|---|---|
Market Cap | $17.40B | $20.42B |
Sector | Health | Consumer Staples |
52-Week High | $180.55 | $68.75 |
52-Week Low | $123.10 | $50.72 |
Enterprise Value | $16.49B | $28.01B |
Dividend Yield | — | 3.52% |
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →